Peps
What is ARA-290?
ARA-290, also called cibinetide, is an erythropoietin-derived peptide investigated in tissue-protection research. A small clinical pilot examined neuropathy symptoms in people with sarcoidosis.
Biological role or research focus
Small-fiber neuropathy research.
A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Role reference: Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. · 2012 ↗
Names you may encounter
Cibinetide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Erythropoietin-derived investigational peptide
- Research focus
- Small-fiber neuropathy research
- Featured evidence
- Human randomized pilot trial
- Source check
- October 4, 2026
Biology & proposed mechanism
Its design separates proposed tissue-protective signaling from erythropoietin’s red-blood-cell effects. The pilot measured clinical symptoms rather than establishing nerve regeneration.
Research context & identity
The featured trial concerns sarcoidosis-associated small-fiber neuropathy. It does not establish effectiveness for every form of pain, neuropathy, or injury.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized pilot trial · 2012
Sarcoidosis-associated small-fiber neuropathy pilot
What did this publication test, and what did it find?
- Population / model
- 22 people with sarcoidosis and small-fiber neuropathy.
- Study design
- Randomized double-blind placebo-controlled pilot over four weeks.
- Main finding
- The small-fiber-neuropathy symptom score improved more with ARA-290. Brief Pain Inventory pain and fatigue measures improved similarly in both groups; depression did not change.
- Limits & context
- A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Human placebo-controlled trial · 2013
ARA 290 · nerve-fiber outcomes
Did a later short study add objective nerve measures?
- Population / model
- Patients with sarcoidosis and documented small nerve-fiber loss; the abstract does not state the sample size.
- Study design
- Blinded placebo comparison over 28 days, assessing neuropathic symptoms, corneal nerve density, sensory testing, and walking capacity.
- Main finding
- The report described improved neuropathic symptoms, increased corneal small nerve-fiber density, altered temperature sensitivity, and greater six-minute walking capacity.
- How to read it
- An objective corneal measure complements symptom reports but is not proof of durable recovery throughout the nervous system.
- Limits & context
- The abstract omits effect sizes and participant count. Short follow-up and a specific disease setting limit generalization. Full methods and longer-term replication need review before making a disease-modifying claim.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
The pilot did not identify a clinical or laboratory safety concern, but its size and duration provide limited information about uncommon or delayed harms.
Evidence boundaries
A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
11 matching video records · 2 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Fouad Abiad Media
RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Peptide Of The Week
Telehealth vs Research Peptides: The Truth Nobody Tells You | Peptide of the Week Q&A #61 ↗
Captions indexed · Automatic matches need review
Biohackingturkey
ARA-290 Gerçekten İşe Yarıyor mu? (Bilimsel İnceleme) ↗
Title match · Captions not indexed
Biohackingturkey
ARA-290 Nedir? Sinir Hasarını Onaran Mucize Peptit! ↗
Title match · Captions not indexed
Biohackingturkey
ARA-290 Peptit Nedir? Sinir Hasarını Onaran Mucize Molekül ↗
Title match · Captions not indexed
Biohackingturkey
ARA290 Hakkında Bilmeniz Gereken 5 Şaşırtıcı Gerçek! ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
ARA-290 (15mg)
BioLongevity Labs · Vendor-labeled research use only
$95.00
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
ARA-290 (10 mg)
American Peptides · Vendor-labeled research use only
$82.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
ARA-290 (10 mg)
PSPeptides · Vendor-labeled research use only
$59.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Did every pain outcome improve more than placebo?
- What material, population, and route were actually studied?
- A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did every pain outcome improve more than placebo?
No. The report distinguished an improved neuropathy symptom score from pain and fatigue measures that improved similarly in both groups.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.